Corporate

• Represented Mega Genomics, the largest consumer genetic testing platform in China, in its HK$215 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange.
• Represented Huatai Financial for Sino-Synergy Hydrogen Energy Technology’s HK$1.56 billion global offering and IPO on the Main Board of the Hong Kong Stock Exchange. Huatai Financial acted as the sole sponsor for this offering. Sino-Synergy Hydrogen Energy Technology is a leading Chinese technology and hydrogen fuel cell company focused on the research, development, production and sales of hydrogen fuel cell stacks and hydrogen fuel cell systems.
• Representing several global investment banks in the Hong Kong IPO listing process, including the corporate AML/FCPA/OFAC anti-corruption due diligence process, of a national rural service company.

Compliance

• Represented a world-leading pharmaceutical/medical device company in multiple internal investigations of their operations in the Greater China region in connection with whistleblower allegations, FCPA-related, anti-bribery, anti-corruption and anti-fraud concerns, off-label promotion, consumer and distributor complaints, external funding with GOs (sponsorships), interactions with and fee-for-service payments to HCPs, and various expense issues involving third-party business partners (such as distributors, service vendors, and travel agencies, among others).
• Seconding to the Legal and Compliance Department of a world-leading medical device company on medical equipment regulatory management, business partner management, and other general corporate regulatory issues.
• Advised several multinational life science companies on various regulatory issues, such as the “two-invoice” system and the U.S. export control enforcement against distributors and vendors.